Overactive Bladder

BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that the Company believes can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October 2016, UroGen announced the licensing of the worldwide rights to BotuGel to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc.